Stealth BioTherapeutics announced completion of enrollment for MMPOWER-3, with top-line data expected by year end. MMPOWER-3 is a Phase 3, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of daily subcutaneous injections of elamipretide in patients with primary mitochondrial myopathy followed by an open-label treatment extension.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.